Search

Author/Creator de Jong, E

1. 1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (23rd October 2018)

Authors:
Dummer, R; Schadendorf, D; Hauschild, A; Santinami, M; Atkinson, V G; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Kirkwood, J M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1251PAdverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (23rd October 2018)

Authors:
Atkinson, V G; Hauschild, A; Santinami, M; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Schadendorf, D; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Dummer, R; Kirkwood, J M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗